John Houston, departing Arvinas CEO
July 9, 2025 01:47 PM EDTUpdated 02:05 PM
People

Q&A: Re­tir­ing Arv­inas CEO John Hous­ton talks PRO­TACs, in­vestor con­fi­dence and what’s next with Pfiz­er

Max Gelman

Senior Editor

Arv­inas CEO John Hous­ton is plan­ning to re­tire af­ter more than eight years at the helm, the com­pa­ny an­nounced Wednes­day, as its lead pro­tein de­grad­er …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Who pays the most in bio­phar­ma? We an­a­lyzed me­di­an pay at 177 com­pa­nies

Up­dat­ed: Mer­ck drops $10B for res­pi­ra­to­ry drug­mak­er Verona Phar­ma in its first ac­qui­si­tion of 2025

Fed­er­al judge sides with FDA on its mifepri­s­tone safe­ty pro­gram

Bio­phar­ma's 20 high­est-paid CEOs of 2024 with $20M+ pay­days

As­traZeneca’s Alex­ion inks AAV cap­sid deal with JCR Phar­ma

sponsored

Un­cov­er­ing the Po­ten­tial of Tar­get­ing the CD38 Path­way for Im­mune-Me­di­at­ed Dis­eases

A service from the Financial Times